Hemovás (Pentoxifylline)

Hemovás (pentoxifylline) is prescribed for several circulatory disorders where improved blood flow can relieve symptoms and support tissue healing. It is typically considered when conventional therapies have not achieved adequate perfusion.

• Peripheral arterial disease (PAD) to reduce intermittent claudication.
• Intermittent claudication associated with lower‑extremity arterial insufficiency.
• Chronic venous ulcers where microcirculatory improvement aids healing.
• Peripheral vascular disease with reduced erythrocyte flexibility.
• Adjunct therapy for patients with diabetic foot ulcers when vascular compromise is present.

Side‑effect profiles for intravenous pentoxifylline reflect its influence on blood viscosity and vascular tone.

Common

• Nausea or mild gastrointestinal discomfort.
• Headache or dizziness.
• Flushing or warmth sensation.
• Transient hypotension after infusion.
• Mild increase in heart rate.
• Nausea, vomiting, or abdominal cramping.
• Dizziness or light‑headedness.
• Transient tachycardia.
• Mild insomnia or sleep disturbance.
• Transient visual disturbances such as blurred vision.

Serious

• Severe hypotension or shock.
• Acute hemolysis or anemia.
• Allergic reactions such as rash, bronchospasm, or anaphylaxis.
• Bleeding complications due to platelet dysfunction.
• Renal impairment or worsening kidney function.
• Severe hepatic dysfunction in predisposed patients.

These events are generally dose‑related and may resolve after discontinuation or dose adjustment.

When prescribing Hemovás, clinicians should evaluate patient history and monitor for conditions that could be aggravated by altered blood flow or phosphodiesterase inhibition.

• Known hypersensitivity to pentoxifylline or any formulation components.
• Uncontrolled hypertension or recent myocardial infarction.
• Active bleeding disorders or concurrent anticoagulant therapy.
• Severe liver or kidney disease that may affect drug clearance.
• Pregnancy, lactation, or women of child‑bearing potential without risk assessment.
• Patients with retinal vascular disorders.
• Use in children only when benefits outweigh risks.

Pentoxifylline can modify the effects of several medications, therefore careful review of concomitant drugs is recommended.

Avoid

• Strong CYP1A2 inhibitors such as fluvoxamine or ciprofloxacin.
• Anticoagulants like warfarin when high bleeding risk is present.
• Other phosphodiesterase inhibitors (e.g., milrinone) that may potentiate hypotension.
• Alpha‑adrenergic blockers (e.g., prazosin) that may cause additive vasodilation.

Use with caution

• Antihypertensive agents (e.g., ACE inhibitors, beta‑blockers) – monitor blood pressure.
• Diuretics – watch for electrolyte disturbances.
• NSAIDs – increased risk of renal impairment.
• Antiplatelet drugs (e.g., clopidogrel) – assess bleeding tendency.
• Cimetidine – may increase pentoxifylline plasma levels.
• Monitor renal function when combined with nephrotoxic agents.